At the news
? NEUTRALIMPACT 5/10 6-K filed May 18, 2026 at 16:01 ET
Alpha Tau reported Q1 2026 financial results with net loss widening to $22.9M ($0.26/share) from $8.7M ($0.12/share) YoY, driven by a $9.6M non-cash remeasurement of warrants liability and increased R&D spend. Operationally, the company highlighted strong interim REGAIN glioblastoma data (67% complete response rate), completion of enrollment in the pivotal ReSTART cSCC trial (88 patients), and PMDA approval in Japan. Cash of $80.2M provides runway into 2027.
- Net loss of $22.9M in Q1 2026 vs $8.7M in Q1 2025; EPS -$0.26 vs -$0.12
- Operating loss widened to $13.3M from $9.3M YoY, driven by R&D spend up to $11.0M from $7.2M
- Financial expense of $9.6M vs income of $0.7M YoY due to warrants liability remeasurement
- Cash, equivalents, short-term and restricted deposits of $80.2M at March 31, 2026 vs $76.9M at Dec 31, 2025
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access